These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33919658)

  • 21. Drug-Eluting Beads versus Lipiodol Transarterial Chemoembolization for the Treatment of Hypovascular Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Shi Q; Chen D; Zhou C; Liu J; Huang S; Yang C; Xiong B
    Cancer Manag Res; 2020; 12():5461-5468. PubMed ID: 32753963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-eluting bead transarterial chemoembolization could improve the hepatic hemodynamics of patients with unresectable hepatocellular carcinoma: a retrospective cohort study.
    Wang T; Du YN; Sun J; Song H; Jiang Y; Liu F; Lv X
    J Gastrointest Oncol; 2023 Feb; 14(1):302-311. PubMed ID: 36915464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma.
    Baur J; Ritter CO; Germer CT; Klein I; Kickuth R; Steger U
    Hepat Med; 2016; 8():69-74. PubMed ID: 27382341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus
    Ludwig JM; Zhang D; Xing M; Kim HS
    Eur Radiol; 2017 May; 27(5):2031-2041. PubMed ID: 27562480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres
    Ma Y; Zhao C; Zhao H; Li H; Chen C; Xiang H; Zheng C; Ma C; Luo C; Qiu H; Yao Y; Hu H; Xiong B; Zhou J; Zhu H; Long Q
    Am J Transl Res; 2019; 11(12):7456-7470. PubMed ID: 31934293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
    Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O
    Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic body radiation therapy following transarterial chemoembolization for unresectable hepatocellular carcinoma.
    Buckstein M; Kim E; Fischman A; Blacksburg S; Facciuto M; Schwartz M; Rosenzweig K
    J Gastrointest Oncol; 2018 Aug; 9(4):734-740. PubMed ID: 30151270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arterial-Portal Venous Shunt after Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma Patients: Risk factors and Impact on Patient Survival.
    Hien PN; Chun HJ; Oh JS; Kim SH; Choi BG
    Oncology; 2024 Feb; ():. PubMed ID: 38408447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Huang K; Zhou Q; Wang R; Cheng D; Ma Y
    J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
    Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
    World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma.
    Arabi M; BenMousa A; Bzeizi K; Garad F; Ahmed I; Al-Otaibi M
    Saudi J Gastroenterol; 2015; 21(3):175-80. PubMed ID: 26021777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiofrequency and microwave ablation in combination with transarterial chemoembolization induce equivalent histopathologic coagulation necrosis in hepatocellular carcinoma patients bridged to liver transplantation.
    Vasnani R; Ginsburg M; Ahmed O; Doshi T; Hart J; Te H; Van Ha TG
    Hepatobiliary Surg Nutr; 2016 Jun; 5(3):225-33. PubMed ID: 27275464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug-eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma.
    Chen S; Yu W; Zhang K; Liu W; Chen C
    Hepatol Res; 2021 Apr; 51(4):482-489. PubMed ID: 33462925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initial Experience of Drug-Eluting Bead-Transcatheter Arterial Chemoembolization After Lipiodol-Based Transcatheter Arterial Chemoembolization Failure for Patients with Advanced Hepatocellular Carcinoma.
    Liu KC; Lv WF; Lu D; Hou CL; Xie J; Lu YH; Cao QS; Tan YL; Zhang YZ; Liu J
    Cancer Manag Res; 2021; 13():7973-7980. PubMed ID: 34703317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma.
    Liu YS; Ou MC; Tsai YS; Lin XZ; Wang CK; Tsai HM; Chuang MT
    Korean J Radiol; 2015; 16(1):125-32. PubMed ID: 25598680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-eluting bead transarterial chemoembolization is efficient and well-tolerated in treating elderly Chinese hepatocellular carcinoma patients.
    Zhou Y
    Int J Clin Exp Pathol; 2018; 11(10):4867-4878. PubMed ID: 31949562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conventional Transarterial Chemoembolization Versus Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Bzeizi KI; Arabi M; Jamshidi N; Albenmousa A; Sanai FM; Al-Hamoudi W; Alghamdi S; Broering D; Alqahtani SA
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-eluting bead transarterial chemoembolization in the treatment for unresectable soft tissue sarcoma refractory to systemic chemotherapy: a preliminary evaluation of efficacy and safety.
    Ni JY; Sun HL; Chen YT; Luo JH; Wang WD; Jiang XY; Chen D; Xu LF
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):157-163. PubMed ID: 28993945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of survival and prognostic factors in treatment of hepatocellular carcinoma in Spanish patients with drug-eluting bead transarterial chemoembolization.
    Sánchez-Delgado J; Vergara M; Machlab S; Lira A; Gómez Zaragoza C; Criado E; Rosinach M; Batista L; Arau B; Roget M; Ortiz J; Garcia C; Sort P; Casas M; Dalmau B; Forné M; Falcó J; Miquel M
    Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1453-1460. PubMed ID: 30113926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.